Join
Live feed
·
PRReleasevia Quantisnow
Werewolf Therapeutics Inc. logo

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

ByQuantisnow·Wall Street's wire, on your screen.
HOWL· Werewolf Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HOWL (Werewolf Therapeutics Inc.) and more on Quantisnow.